United Therapeutics Corporation (NASDAQ: UTHR ) is at the forefront of innovation in the biotechnology and pharmaceutical industry. Its portfolio of FDA-approved products treats pulmonary arterial hypertension (PAH) and related cardiovascular conditions. The company's wide treatment options, including oral and injectable therapies like Orenitram, Remodulin, and Adcirca, strengthenMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politec ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

United Therapeutics’ (UTHR) third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.Revenues totaled $748.9 million, which beat the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin.See the Zacks Earnings Calendar to stay ahead of market-making news.More on UTHR’s EarningsUnited Therapeutics markets fo ...

财务数据和关键指标变化 - 公司在2024年第三季度实现了创纪录的收入，总额为7.49亿美元，同比增长23% [17] - 公司在过去八个季度内实现了从20亿美元到30亿美元的收入跑道，标志着显著的增长 [17] 各条业务线数据和关键指标变化 - Tyvaso的收入为4.34亿美元，同比增长33%，主要受益于DPI的持续增长和PH-ILD患者的使用增加 [18] - Orenitram的收入为1.13亿美元，同比增长23%，同样受益于需求增加和定价调整 [21] - Remodulin的全球收入为1.28亿美元，同比下降2%，但美国收入增长3% [22] - Unituxin的收入为6100万美元，同比增长19% [24] 公司战略和发展方向和行业竞争 - 公司在创新和革命波浪中持续推进，预计在未来36个月内将有一系列重要的临床数据发布和监管决策 [10][11] - 公司计划在2025年获得FDA对其中央肺评估系统的行动 [10] - 公司在资本配置方面，优先考虑投资于商业和研发机会、智能业务发展机会以及回报股东 [14][15] 管理层对经营环境和未来前景的评论 - 管理层对当前商业业务的潜力表示信心，预计将继续推动中短期内的双位数收入增长 [9] - 管理层强调，尽管面临竞争，Remodulin仍然是治疗肺动脉高压患者的首选药物，未来仍将保持强劲的市场需求 [43][46] 其他重要信息 - 公司在第三季度记录了6500万美元的诉讼准备金，涉及Sandoz案件的潜在判决 [16] - 公司在第三季度完成了与Citi的10亿美元加速股票回购计划，回购了约350万股股票 [12][13] 问答环节所有提问和回答 问题: 关于Orenitram的患者转移情况 - 管理层表示，虽然有部分患者从Remodulin转移到Orenitram，但尚未形成广泛趋势，预计Orenitram的平均剂量将随着患者的转移而增加 [27][28] 问题: Nebulized Tyvaso的增长驱动因素 - 管理层指出，Nebulized Tyvaso的增长部分是由于去年库存的去库存，当前DPI和Nebulizer的比例大约为2/3对1/3 [32] 问题: Tyvaso DPI的生产能力 - 管理层确认，现有的生产设施能够支持IPF的批准，不需要额外投资 [38] 问题: 关于未来的股票回购计划 - 管理层表示，未来将继续评估资本配置的各个优先事项，包括可能的股票回购计划，但目前尚未具体确定 [40] 问题: Remodulin的市场表现 - 管理层对Remodulin的市场表现表示乐观，认为其在肺动脉高压治疗中的地位将继续保持 [45][46] 问题: UKidney的临床试验设计 - 管理层表示，关于UKidney的临床试验设计将在获得FDA的IND批准后分享更多细节 [51] 问题: 未来的收入目标 - 管理层确认，预计将继续实现双位数的年度收入增长，目标是到2025年达到40亿美元的收入跑道 [55]

United Therapeutics (UTHR) reported $748.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 22.9%. EPS of $6.39 for the same period compares to $5.38 a year ago.The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $717.49 million. With the consensus EPS estimate being $6.18, the EPS surprise was +3.40%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...

United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.40%. A quarter ago, it was expected that this drugmaker would post earnings of $6.33 per share when it actually produced earnings of $5.85, delivering a surprise of -7.58%. Over the last four quarters, the c ...

Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 30, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the cl ...

财务状况 - 公司总资产为 XXX 亿元 [1] - 公司总负债为 XXX 亿元 [1] - 公司净资产为 XXX 亿元 [1] - 公司资产负债率为 XX% [1] 营业收入 - 公司本期营业收入为 XXX 亿元 [2] - 公司营业收入同比增长 XX% [2] - 公司主营业务收入占营业收入的 XX% [2] 盈利能力 - 公司本期净利润为 XXX 亿元 [3] - 公司净利润同比增长 XX% [3] - 公司毛利率为 XX% [3] - 公司净利率为 XX% [3] 现金流 - 公司经营活动产生的现金流量净额为 XXX 亿元 [4] - 公司投资活动产生的现金流量净额为 XXX 亿元 [4] - 公司筹资活动产生的现金流量净额为 XXX 亿元 [4] - 公司现金及现金等价物净增加额为 XXX 亿元 [4]